Athenex Announces Licensing Agreement with PharmaEssentia for Rights to Oradoxel (Oral Docetaxel) in Certain Asian Territories
November 29, 2018 07:07 ET
|
Athenex, Inc.
BUFFALO, N.Y., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex宣佈啟動Oraxol結合抗PD1抗體的第I/II階段臨床試驗
November 26, 2018 19:45 ET
|
Athenex, Inc.
美國紐約州水牛城, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX) 為一間致力研發、開發治療癌症和相關疾病新療法並將其商業化的全球性生物製藥公司。Athenex今日宣佈已經與Mayo Clinic合作啟動一項第I/II階段臨床試驗，評估Oraxol結合抗PD1抗體 (pembrolizumab)...
Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1
November 26, 2018 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc. 公佈2018年第三季度財務業績並提供最新公司業務資訊
November 16, 2018 02:51 ET
|
Athenex, Inc.
第三季度收入增至1,840萬美元，而2017年第三季度為1,400萬美元 資料及安全監測委員會(「DSMB」) 積極推薦Oraxol 於第III階段臨床試驗的第二次中期分析結果 KX2-391第三階段臨床關鍵性研究已實現主要終點 Oratecan和Oradoxel準備進入第II階段臨床試驗 Athenex將於今日美國東岸時間上午8時正舉行電話會議和現場音頻網絡直播 美國紐約州水牛城,...
Athenex, Inc. Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 14, 2018 07:00 ET
|
Athenex, Inc.
Third quarter revenue increased to $18.4 million compared to $14.0 million in 3Q 2017 Positive recommendation by DSMB upon second interim analysis for Oraxol Phase III program KX2-391 Phase III...
Athenex, Inc.將於2018年11月14日公佈第三季度盈利業績
November 01, 2018 07:00 ET
|
Athenex, Inc.
紐約州布法羅, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Athenex,...
Athenex, Inc. to Report Third Quarter Earnings Results on November 14, 2018
November 01, 2018 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex宣布FDA批准Eribulin ORA研究性新藥開展臨床試驗的申請
October 29, 2018 16:06 ET
|
Athenex, Inc.
美國紐約州水牛城, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.（Nasdaq: ATNX）是一家專門致力於開發、研製並將治療癌症和相關疾病的新療法商業化的全球生物製藥公司， 今天宣布FDA已批准Athenex口服Eribulin研究性新藥（IND）（目前名為Eribulin ORA）的臨床試驗申請。 ...
Athenex Announces FDA Allowance of Investigational New Drug Application of Eribulin ORA to Begin Clinical Trials
October 29, 2018 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
歐洲腫瘤內科學會（ESMO）2018年大會：Athenex呈報Oraxol治療轉移性乳腺癌令人鼓舞的臨床試驗療效和安全性結果
October 22, 2018 17:19 ET
|
Athenex, Inc.
紐約州水牛城, Oct. 23, 2018 (GLOBE NEWSWIRE) -- 致力於發現、開發並將治療癌症和相關疾病的新療法商業化的環球生物製藥公司Athenex（Nasdaq:...